Kalaris Therapeutics heads into its May 20 earnings event with shorts aggressively rebuilding after months of unwinding — just days after a Q1 beat failed to stop the stock sliding.
The short interest story here is the standout. Estimated short interest jumped 30% in one week to 4.2% of float — the sharpest weekly build in months. That follows a sharp single-session surge of roughly 33% on May 12, the day Q1 results landed. The stock beat estimates with an EPS of $(0.46) versus the $(0.53) consensus, yet it fell 9.6% on the week regardless. Shorts smell something beyond the headline number. The history makes the rebuild even more striking: short interest has nearly halved from its mid-April peak of over 1.1 million shares to around 795,000, but the reversal this week suggests that unwind has stalled.
The borrow market is loose, which matters for reading the shorts' intent. Availability is ample — utilization at just 17% is well below the 52-week high of 80%, meaning the lending pool is far from stretched. Cost to borrow is running at a benign 3.4%, up around 9% on the week but low in absolute terms. There is no squeeze pressure here. When availability is this loose, the short rebuild reflects genuine conviction rather than forced positioning — bears can add comfortably and they appear to be doing so.
The Street picture adds an interesting layer. Coverage is unanimously bullish in rating, with Citizens today maintaining its Market Outperform but nudging the price target down to $25 from $26 — a modest trim but a signal of recalibration. Morgan Stanley initiated coverage last month at Overweight with a $14 target, notably below the consensus mean of around $19. That gap between the most cautious and most optimistic targets is wide for a name this small, reflecting genuine disagreement about how far TH103, the company's lead anti-VEGF candidate, can go. The bull case rests on clinical differentiation and a market Vabysmo has proved enormous — over $4 billion in global sales. The bear case is blunt: no revenue, accumulated losses, and a long road to commercialisation at minimum. The ORTEX analyst recommendation percentile ranks at 97th — meaning the Street is more bullish on KLRS relative to the broader universe — yet the factor scores elsewhere are tepid, with EPS momentum at just the 28th percentile over 30 days.
Ownership is concentrated. Samsara BioCapital holds 56% of shares, a position reinforced by a $15 million open-market buy in December at $10 per share. That anchor creates both a support floor and a liquidity overhang — with the stock now at $4.79, Samsara is deeply underwater on that purchase. A $100 million at-the-market offering agreement launched with TD Cowen in mid-April adds further dilution risk, and may explain some of the renewed short pressure seen this week.
The earnings reaction history is worth noting. The March event produced a 1-day move of -14.5% and a 5-day move of -29.6%. The prior earnings in November 2025 saw the stock gain 10% on the day but then surge 39% over five days — a reminder of how binary these events can be for a pre-revenue biotech. With the next event on May 20, the ORTEX short score at 67 (elevated), and shorts rebuilding into the announcement, the key tension to track is whether clinical update language from management shifts the narrative — or whether the pattern of post-earnings selling reasserts itself.
See the live data behind this article on ORTEX.
Open KLRS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
